{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:08:16Z","timestamp":1788822496191,"version":"build-2803163510"},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1055\/a-2855-5598","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:36:47Z","timestamp":1788820607000},"page":"1003-1013","source":"Crossref","is-referenced-by-count":0,"title":["Neuroendokrine Tumoren des Gastrointestinaltraktes"],"prefix":"10.1055","volume":"151","author":[{"given":"Anja","family":"Rinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Eilsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Stathopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.24750","article-title":"Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States","volume":"4","author":"Z Xu","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms","volume":"33","author":"G Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13318","article-title":"European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes","volume":"35","author":"J Hofland","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1055\/a-0604-2924","article-title":"S2k-Leitlinie Neuroendokrine Tumore","volume":"56","author":"A Rinke","year":"2018","journal-title":"Z Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13306","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3","volume":"35","author":"F Panzuto","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13309","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours","volume":"35","author":"A Rinke","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/JCO.2015.64.0987","article-title":"Prospective Study of 68Ga-DOTATATE Positron Emission Tomography\/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites","volume":"34","author":"SM Sadowski","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003409","article-title":"International, multicenter analysis of endoscopic full-thickness resection of duodenal neuroendocrine tumors","author":"A Wannhoff","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"A Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"ME Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors","volume":"392","author":"JA Chan","year":"2025","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)","volume":"41","author":"PL Kunz","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1158\/0008-5472.CAN-12-3923","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"JC Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"E Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"S Singh","year":"2024","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"J Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"S 16","key":"ref17","doi-asserted-by":"publisher","first-page":"abstr 4122","DOI":"10.1200\/JCO.2022.40.16_suppl.4122.18","article-title":"Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II Studies ofLu-Octreotate Peptide Receptor Radionuclide Therapy (LuTate PRRT) +\/\u2212 Capecitabine, Temozolomide (CAPTEM) or CAPTEM Alone for Neuroendocrine Tumours(NETs)","volume":"40","author":"N Pavlakis","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.2967\/jnumed.120.258889","article-title":"First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy","volume":"62","author":"RP Baum","year":"2021","journal-title":"J Nucl Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States","volume":"3","author":"A Dasari","year":"2017","journal-title":"JAMA Oncol"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2855-5598.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:36:51Z","timestamp":1788820611000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2855-5598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":19,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9,7]]},"published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2855-5598","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}